The pandemic is scrambling pharma’s business model
While dozens of drug companies are racing to develop therapies and vaccines for the novel coronavirus, countless others are struggling with one of its practical effects: It’s hard to run a sales force in a pandemic.
As STAT’s Adam Feuerstein reports, Amgen and Merck have ordered their sales reps to halt all in-person meetings with doctors and hospitals. Amarin, maker of the heart drug Vascepa, instituted a two-week suspension of all face-to-face sales interactions.
Whether this will have an effect on companies’ bottom lines remains to be seen. No one knows when the outbreak might wane, and drugs tend to be must-have goods for consumers, meaning it’s unlikely patients won’t refill prescriptions because of coronavirus.
Read more.
As STAT’s Adam Feuerstein reports, Amgen and Merck have ordered their sales reps to halt all in-person meetings with doctors and hospitals. Amarin, maker of the heart drug Vascepa, instituted a two-week suspension of all face-to-face sales interactions.
Whether this will have an effect on companies’ bottom lines remains to be seen. No one knows when the outbreak might wane, and drugs tend to be must-have goods for consumers, meaning it’s unlikely patients won’t refill prescriptions because of coronavirus.
Read more.
.png)
No hay comentarios:
Publicar un comentario